폴라리스AI파마
Financials
Valuation Metrics
폴라리스AI파마's Market Cap is ₩719B. At end of 2025 it was ₩828B. Ranked #1517 of 2,421 in KR market (top 63%), #888 of 1,640 on KOSDAQ (top 54%), #164 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 71.86B KRW | KR#1,517/2,421 Sec#164/231 |
| Revenue | 57.37B KRW | KR#1,721/2,421 Sec#116/231 |
| Net Income | 14.28B KRW | KR#834/2,421 Sec#56/231 |
| Total Assets | 196.69B KRW | KR#1,320/2,421 Sec#96/231 |
| Net Assets | 147.88B KRW | KR#1,146/2,421 Sec#81/231 |
| Employees | 164 | KR#1,246/2,421 Sec#102/231 |
| Value | ||
| P/E | 5.03x | KR#352/2,421 Sec#12/231 |
| P/B | 0.49x | KR#774/2,421 Sec#34/231 |
| PEG | 0.02x | KR#213/2,421 Sec#11/231 |
| P/S | 1.25x | KR#1,527/2,421 Sec#88/231 |
| EV/EBITDA | 28.80x | KR#1,180/2,421 Sec#72/231 |
| FCF Yield | 11.52% | KR#551/2,421 Sec#19/231 |
| Profitability | ||
| ROE | 9.66% | KR#645/2,421 Sec#44/231 |
| ROA | 7.26% | KR#491/2,421 Sec#38/231 |
| Op. Margin | 4.47% | KR#1,028/2,421 Sec#74/231 |
| Revenue Growth | 0.72% | KR#1,486/2,421 Sec#147/231 |
| Earnings Growth | 207.19% | KR#240/2,421 Sec#15/231 |
| Financial Health | ||
| Debt Ratio | 33.01% | KR#651/2,421 Sec#76/231 |
| Total Debt | 36.50B KRW | KR#1,137/2,421 Sec#81/231 |
| FCF | 8.28B KRW | KR#765/2,421 Sec#43/231 |
| Cash | 34.54B KRW | KR#920/2,421 Sec#61/231 |
| Current Ratio | 8.31x | KR#138/2,421 Sec#29/231 |
| Net Debt/EBITDA | 0.76x | KR#708/2,421 Sec#46/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -17.40% | KR#1,187/2,421 Sec#81/231 |
| 1M Return | 5.46% | KR#721/2,421 Sec#52/231 |
| From 52W High | -46.96% | KR#1,248/2,421 Sec#93/231 |
| 1Y MDD | -51.79% | KR#1,059/2,421 Sec#86/231 |
| Trading | ||
| Volume | 13,970 shares | KR#1,772/2,421 Sec#176/231 |
| Trading Value | 76.3M KRW | KR#1,672/2,421 Sec#170/231 |
| Foreign Own. | 1.68% | KR#1,765/2,421 Sec#170/231 |
| Per Share | ||
| EPS | 1,075 KRW | KR#695/2,421 Sec#47/231 |
| BPS | 11,132 KRW | KR#920/2,421 Sec#63/231 |
Company Info
Established in 1999 and listed on KOSDAQ in 2004, the company became an affiliate of Polaris Group in 2024, benefiting from group human resources and AI technology collaboration. It produces over 60 types of active pharmaceutical ingredients (APIs) using organic synthesis and chiral technologies, conducting both API and CDMO businesses. The company aims to expand its CDMO services to include development and production, adapting to AI technology shifts in the pharmaceutical and bio industries, including AI new drugs. Polaris AI Pharma was founded in 1998 and is headquartered in Hwaseong-si, Gyeonggi-do.